|
Market Closed -
Nasdaq
21:00:00 18/09/2026 BST
|
5-day change | 1st Jan Change | ||
| 78.09 USD | -1.19% |
|
-1.54% | -4.63% |
Company Valuation: Tarsus Pharmaceuticals, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 465.2 | 391 | 670.4 | 2,117 | 3,476 | 3,427 | - | - |
| Change | - | -15.95% | 71.44% | 215.74% | 64.21% | -1.41% | - | - |
| Enterprise Value (EV) | 465.2 | 391 | 472.1 | 1,894 | 3,476 | 3,427 | 3,427 | 3,427 |
| Change | - | -15.95% | 20.74% | 301.19% | 83.5% | -1.41% | 0% | 0% |
| P/E | -33.6x | -5.82x | -4.38x | -18x | -51.5x | -36.6x | 33.6x | 16.2x |
| PBR | - | - | - | - | - | - | - | - |
| PEG | - | -0x | -0.1x | 0.5x | 1.1x | -1.1x | -0x | 0x |
| Capitalization / Revenue | 8.16x | 15.1x | 38.4x | 11.6x | 7.7x | 4.79x | 3.76x | 3.19x |
| EV / Revenue | 0x | 0x | 0x | 0x | 0x | 4.79x | 3.76x | 3.19x |
| EV / EBITDA | -0x | -0x | -0x | -0x | -0x | -37x | 22.5x | 8.34x |
| EV / EBIT | -0x | -0x | -0x | -0x | -0x | -34.1x | 26.4x | 11.7x |
| EV / FCF | 0x | - | - | - | -0x | -29.9x | 98.3x | 15.5x |
| FCF Yield | 0.68% | - | - | - | -0.64% | -3.34% | 1.02% | 6.44% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -0.67 | -2.52 | -4.62 | -3.07 | -1.59 | -2.132 | 2.325 | 4.817 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 57.03 | 25.82 | 17.45 | 183 | 451.4 | 714.9 | 910.3 | 1,075 |
| EBITDA 1 | -11.84 | -62.39 | -142.3 | -119.8 | -69.15 | -92.72 | 152.4 | 410.8 |
| EBIT 1 | -12.16 | -62.71 | -143.2 | -120.6 | -70.97 | -100.4 | 129.7 | 293.6 |
| Net income 1 | -13.83 | -62.09 | -135.9 | -115.6 | -66.42 | -95.74 | 115.9 | 261.7 |
| Net Debt | - | - | -198.3 | -222.5 | - | - | - | - |
| Reference price 2 | 22.50 | 14.66 | 20.25 | 55.37 | 81.88 | 78.09 | 78.09 | 78.09 |
| Nbr of stocks (in thousands) | 20,677 | 26,672 | 33,105 | 38,227 | 42,449 | 43,883 | - | - |
| Announcement Date | 14/03/22 | 13/03/23 | 27/02/24 | 25/02/25 | 23/02/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -36.63x | - | - | -.--% | 3.43B | |
| 18.18x | 4.21x | 9.88x | 0.5% | 78.35B | |
| -18.37x | 27.54x | -17.88x | -.--% | 61.52B | |
| 20.55x | 4.37x | 13.55x | 2.4% | 59.78B | |
| 34.06x | 11.59x | 22.22x | -.--% | 46.53B | |
| 20.79x | 4.6x | 13.1x | 0.7% | 45.5B | |
| 35.15x | 3.52x | 13.21x | -.--% | 31.84B | |
| 55.92x | 3.56x | 27.61x | -.--% | 25.4B | |
| 63.43x | 6.8x | 40.64x | -.--% | 21.43B | |
| 23.43x | 5.03x | 13.09x | -.--% | 15.77B | |
| Average | 21.65x | 7.91x | 15.04x | 0.36% | 38.96B | |
| Weighted average by Cap. | 21.04x | 8.96x | 11.17x | 0.55% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- TARS Stock
- Valuation Tarsus Pharmaceuticals, Inc.
Select your edition
All financial news and data tailored to specific country editions
